Veryan Holdings Limited Secures £3.6M

Veryan Holdings Limited, a UK-based developer of a technology for treating the Peripheral Vascular Disease, has secured £3.6m (approximately US$5.4m) in additional funding.
The round was led by new investor Seroba Kernel, a European life science venture capital firm, with participation from existing investors Imperial Innovations, Oxford Capital Partners Limited and NESTA.
The funds will be used to finance further development activities and a pivotal clinical trial designed to show the clinical benefit of Veryans’ BioMimics 3D™ stent technology, which is aimed at the treatment of the Peripheral Vascular Disease.

Join the discussion